Related Experiment Video
Updated: Jun 27, 2026

08:32
Building Up Skin Models for Numerous Applications - from Two-Dimensional (2D) Monoculture to Three-Dimensional (3D) Multiculture
Published on: October 20, 2023
Assuring consumer safety without animal testing: a feasibility case study for skin sensitisation.
Gavin Maxwell1, Maja Aleksic, Aynur Aptula
1Unilever Safety & Environmental Assurance Centre (SEAC), Sharnbrook, Bedfordshire, UK. gavin.maxwell@unilever.com
Alternatives to Laboratory Animals : ATLA
|November 26, 2008
Summary
The European Union is banning animal testing for cosmetics, necessitating new non-animal methods for assessing skin sensitization. This study explores new technologies and risk assessment approaches to ensure consumer safety without animal data.
Area of Science:
- Toxicology
- Cosmetic Science
- Regulatory Affairs
Background:
- Allergic Contact Dermatitis (ACD) is a critical safety assessment for cosmetics.
- Current methods rely on animal testing (e.g., mouse Local Lymph Node Assay).
- EU bans on animal testing for cosmetics (effective March 2009) and products tested on animals (effective March 2013) necessitate alternative approaches.
Purpose of the Study:
- To develop and evaluate non-animal (in silico and in vitro) methods for skin sensitization hazard assessment.
- To create new risk assessment strategies integrating novel data types for consumer safety.
- To demonstrate the feasibility of regulatory decisions without new animal data, using skin sensitization as a case study.
Main Methods:
- Evaluation of emerging technologies like 'omics' and informatics.
- Development of new non-animal predictive models for hazard characterization.
- Integration of new data into revised risk assessment frameworks considering human exposure.
Main Results:
- Progress has been made in implementing a conceptual framework for non-animal risk assessment.
- The study explores the feasibility of making consumer safety decisions without relying on new animal testing data.
- Skin sensitization serves as a practical case study for this approach.
Conclusions:
- A strategic framework exists for transitioning to non-animal safety assessments.
- The integration of new technologies and models is crucial for regulatory compliance and consumer safety.
- The presented approach offers a viable path forward for cosmetic ingredient safety evaluation in the EU.
Related Concept Videos
Toxicity Testing in Animals
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

